US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Baudax Bio, Inc. - Common stock (NQ:BXRX)

N/A UNCHANGED
Last Price Updated: 3:50 PM EST, Nov 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Baudax Bio, Inc. - Common stock

Watchlist Alert: Nasdaq Stocks Under $1 Experience Volume Breakouts: KAVL, BXRX, RMED, SMX
Via AB Newswire
News headline image
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio to Present at the Sidoti Virtual Investor Conference
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Closing of $4 Million Public Offering
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Pricing of $4 Million Public Offering
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
Virtual Webinar to be held April 25, 2023 at 10:00 AM Eastern Time 
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. 
Via MarketBeat
News headline image
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
From Baudax Bio, Inc.
Via GlobeNewswire
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Baudax Bio (NASDAQ: BXRX) Launches Phase 2 Clinical Trial Testing BX1000 for Neuromuscular Blockade in Patients Undergoing Surgery
Baudax Bio, Inc. (NASDAQ: BXRX) is engaged as a pharmaceutical company, which is focused on developing innovative products for use 
Via Spotlight Growth
News headline image
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Closing of $5 Million Public Offering
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Pricing of $5 Million Public Offering
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces 1-for-40 Reverse Stock Split
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights
From Baudax Bio, Inc.
Via GlobeNewswire